Advancing drug discovery for schizophrenia.


Journal Article

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

Full Text

Duke Authors

Cited Authors

  • Marder, SR; Roth, B; Sullivan, PF; Scolnick, EM; Nestler, EJ; Geyer, MA; Welnberger, DR; Karayiorgou, M; Guidotti, A; Gingrich, J; Akbarian, S; Buchanan, RW; Lieberman, JA; Conn, PJ; Haggarty, SJ; Law, AJ; Campbell, B; Krystal, JH; Moghaddam, B; Sawa, A; Caron, MG; George, SR; Allen, JA; Solis, M

Published Date

  • October 2011

Published In

Volume / Issue

  • 1236 /

Start / End Page

  • 30 - 43

PubMed ID

  • 22032400

Pubmed Central ID

  • 22032400

Electronic International Standard Serial Number (EISSN)

  • 1749-6632

Digital Object Identifier (DOI)

  • 10.1111/j.1749-6632.2011.06216.x


  • eng

Conference Location

  • United States